. 2019 May 31;8(6):526. doi: 10.3390/cells8060526

Table 3.

CD8⁺ expression in tumor specimens and serum sPD-L1 level in mice, non-muscular invasive bladder cancer (NMIBC) PDXs carriers, depending on specific pharmacological intervention utilized (n = 10 in each subgroup).

No	Tumor Subtype	Subgroup	CD8⁺ Expression, %	sPD-L1, ng/mL	Correlation
1	Primary luminal NMIBC	V	27.6 ± 2.7	17.6 ± 1.4	r = 0.17 p = 0. 4
1	Primary luminal NMIBC	D	33.4 ± 4.1	2.7 ± 0.5 ^†	r = −0.99 p = 0.001
2	Primary basal NMIBC	V	18.5 ± 3.2	21.8 ± 4.3	r = 0.15 p = 0.3
2	Primary basal NMIBC	D	25.7 ± 2.9	4.1 ± 1.3 ^†	r = −0.93 p = 0.001
3	Primary p53 NMIBC	V	3.6 ± 1.1 ^‡	31.5 ± 3.6 ^‡	r = −0.99 p = 0.001
3	Primary p53 NMIBC	D	5.4 ± 2.3 ^‡	8.4 ± 2.8 ^‡†	r = 0.15 p = 0.3
4	Relapsed luminal NMIBC	V	19.2 ± 2.1	25.4 ± 2.0	r = 0.19 p = 0.3
4	Relapsed luminal NMIBC	D	26.1 ± 3.5	6.2 ± 0.8 ^†	r = −0.99 p = 0.001
5	Relapsed basal NMIBC	V	22.5 ± 2.1	18.4 ± 1.3	r = 0.16 p = 0.4
5	Relapsed basal NMIBC	D	27.7 ± 3.8	5.2 ± 1.2 ^†	r = −0.97 p = 0.001
6	Relapsed p53 NMIBC	V	2.1 ± 0.9 ^‡	37.5 ± 3.8 ^‡	r = −0.99 p = 0.001
6	Relapsed p53 NMIBC	D	4.2 ± 1.5 ^‡	10.3 ± 2.1 ^‡†	r = −0.38 p = 0.06

Note: V—vehicle (control subgroup); D—Durvalumab-treated mice; ^† p < 0.05 when compared with relative control subgroup (Student’s t test); ^‡ p < 0.05 when compared with primary both luminal and basal NMIBC subgroups (one-way ANOVA, Tukey’s criterion).